Ascendx Partners with Anwerina to Reach European Markets

Following the recent U.S. Food and Drug Administration (FDA) clearance of its product Acu-Cut, Ascendx Spine is expanding its reach in Europe by partnering with Switzerland-based Anwerina AG. Ascendx, based in Winter Park, Fla., is looking at Austria, Germany and Switzerland as potential new markets for its spine products. The company recently partnered with Spinaxis for distribution in France.

Acu-Cut, which was approved by the FDA in late February, is a uni-pedicular vertebral augmentation system designed to create a cavity for precise bone cement placement. This procedure goes hand in hand with placement of spinal balloons in the standard treatment procedure for vertebral compression fractures (VCFs), the balloon kyphoplasty. Anwerina has had market success with VCF treatments in past years, according to Dr. Christoph C. Karl, Ph.D., Chairman and CEO of the company.

Anwerina is a pharmaceutical and medical device company focused on the surgical treatment of traumatic conditions of the musculoskeletal system.

Ascendx specializes in orthopedic devices for the spine and trauma markets, with a specific focus on VCF treatments.